We propose to continue the Coronary Artery Risk Development in Young Adults (CARDIA) study from July 2018 to June 2023. CARDIA began in 1985-6, enrolling 5,115 black or white men and women 18 to 30 years old in Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA. Comprehensive in-person follow-up exams were conducted at years (Y)2, 5, 7, 10, 15, 20, 25, and 30 (2015-16) and bi-annual phone calls to ascertain events and update contact information have taken place since baseline. Since its inception, CARDIA has contributed to our understanding of the life course of cardiovascular health and disease, black-white disparities in disease, as well as pulmonary, renal and neurologic aging. Additionally, because of our rich longitudinal data and high retention, CARDIA has been at the forefront of developing and employing novel statistical techniques to exploit the longitudinal data structure. To date, 176 ancillary studies have been approved that leverage the valuable scientific resource that the contract has funded. Continued follow up of the cohort and an examination at Y35 will allow us unprecedented scientific opportunities to expand upon the wealth of genetic, lifestyle, biological, psychosocial and neighborhood data to investigate the influence of these factors on the transition from cardiovascular risk to subclinical and early clinical cardiovascular events. CARDIA is the only study to describe the epidemiology of cardiovascular disease at the outset of the epidemics of obesity and diabetes and during critical transitions from early adulthood into middle age. In this contract renewal, we propose to pursue the following scientific objectives: 1) To enhance statistical power to perform analyses of predictors of clinical events; 2) To study the progression of risk factors to subclinical and clinical cardiovascular disease; and, 3) To identify new risk factors or interactions among risk factors that inform disease pathophysiology. We have expanded beyond these stated aims by planning for several innovative and timely ancillary studies to further leverage 35 years of follow-up in the CARDIA cohort. These ancillary studies are led by investigators with a broad set of expertise from within and outside the contract- funded institutions. We will also pursue the following operational goals: 1) to conduct continued cohort follow- up and data collection on clinical events; 2) to continue to foster scientific collaborations; and, 3) to conduct a limited clinical examination of the CARDIA participants as a platform for ancillary study examination components. CARDIA will continue its groundbreaking contributions to cardiovascular and life course research through continued follow-up and surveillance for clinical events, collection of medical records, event adjudication, and continued collaborations with the wide community of investigators within and outside contract-funded institutions. To ensure the lasting impact of the CARDIA study on our understanding of the lifecourse of cardiovascular aging, our team of senior investigators will continue to identify and mentor diverse early stage investigators towards research independence.
|Effective start/end date||7/1/18 → 6/30/23|
- National Heart, Lung, and Blood Institute (HHSN268201800003I-P0003)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.